Crunch time for the SPAC space

This week’s collapse of a deal to spin-off Amicus’s gene therapy work into a Spac followed the crumbling of Heartflow’s plans to float via a blank-cheque company. Such Spac deal terminations are not restricted to the healthcare sector, but they are a sure sign of a trend in retreat.